BioSpace News Archive

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent clinical and development pipeline progress.

CorMedix Inc. today announced that it will report its financial results for the first quarter ended March 31, 2023, after market close on Monday, May 15, 2023, and will host a corporate update conference call at 4:30pm Eastern Time.

Kintara Therapeutics, Inc. today announced that its President and CEO, Robert E. Hoffman , will present a corporate overview at the Sidoti Micro-Cap Virtual Conference being held on May 10 – 11, 2023.

Siemens Healthineers announced its entrance into an agreement to distribute Scopio Labs’ full-field digital cell morphology technology, which will enable clinical laboratorians to examine patient blood cell samples digitally instead of under a microscope.

Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development.

Laronde, the company pioneering Endless RNA™ – a novel, engineered form of RNA that can be programmed to express proteins inside the body for breakthrough treatments – announced that Pablo J. Cagnoni, M.D., will step down from his role as Chief Executive Officer effective May 26, 2023, to become President and Head of Research & Development of Incyte.

Enzolytics, Inc. announced that the Company’s wholly owned subsidiary, Virogenetics (VIRO), will be conducting a pilot clinical trial test for the state owned Bulgarian National Center for Endocrinology to gauge the effectiveness of the ITV-1 immunotherapy on Diabetes.

Groundbreaking research conducted by a team of leading researchers at Entrinsic Bioscience and the University of Florida revealed significant findings that will change the way we understand amino acid combinations and represents the next generation of Oral Rehydration Solutions.

SynCrest Inc., a peptide and nucleotide CRDMO joint venture between Otsuka Chemical Co., Ltd. and Yokogawa Electric Corporation, announces its services are now available for pharmaceutical companies and research institutions in Japan, Europe, North America, and South America.

Neuronetics, Inc., a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced its certification in two enhanced compliance programs.